Summary by Moomoo AI
On June 20, 2024, Redhill Biopharma Ltd., a biopharmaceutical company, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC). The filing pertains to the registration of an additional 800,000,000 ordinary shares, which may be issued under the company's Amended and Restated Award Plan (2010). These shares are represented by American Depositary Shares and are par value NIS 0.01 per share. The company, incorporated in Israel, has its principal executive offices in Tel Aviv and an agent for service located in Raleigh, North Carolina. The registration statement incorporates by reference several documents, including the company's Annual Report on Form 20-F for the year ended December 31, 2023, and various reports on Form 6-K. The company has also detailed its indemnification policies for directors and officers, as well as the conditions under which it may provide insurance and exemptions as per Israeli law and the company's articles of association. The filing includes undertakings by the company regarding the registration statement and the potential need for post-effective amendments.
